September 4, 2008 - Pioneer Surgical Technology Inc. has received 510(k) clearance to market FortrOss, a novel bone graft substitute utilizing the power of nanotechnology for orthopedic applications.
The FortrOss bone void filler is a scaffold for the in-growth of new bone and other connective tissues, when superior bone regeneration is required.
The osteoconductive matrix in FortrOss utilizes Pioneer's nanOss technology and is designed to mimic the nanostructures inherent in boney tissue.
"Because the nanOss hydroxyapatite in FortrOss resembles the size, shape, and chemistry of native bone, boney tissue has a great affinity for nanOss and recognizes it as native tissue,” said Edward Ahn, vice president of biomaterials at Pioneer Surgical. “This mimicry of native bone makes nanOss superior to other calcium phosphates on the market.”
FortrOss is expected to be U.S. market released later this year.
For more information: www.pioneersurgical.com
April 28, 2020 
